Determining cytotoxicity is a critical step in assessing the biocompatibility of medical devices, biomaterials, and drug screening. There are a wide variety of methods available to researchers; however, too often cell-based assay results indicating poor cell health without greater context slow down or halt progress on the development of a medical device. Technology is constantly…

Ensuring that new products get to market is a top priority for R&D teams, as delays can significantly impact ROI. But the actual cost of pre-clinical research delays comes from studies that must be repeated due to incorrect testing. iFyber President, Greg Mouchka, offers insights on how to avoid these expensive mistakes. Challenges in Pre-Clinical…

All medical device manufacturers strive to ensure devices and biomedical technologies are safe, efficacious, and fit for intended use. The biggest roadblock to accomplishing this is medical device testing to determine the most appropriate regimen for the device and its use. Although speed to market is key, medical device manufacturers must devise and implement an…

iFyber participates in the 7th Bioengineering and Translational Medicine Conference in Boston from Wednesday, December 14, 2022 to Friday, December 16, 2022. The selection of suitable cell populations is crucial to the outcome of regenerative medicine. As a potential stem cell source, teeth are easily accessible, harbor several different cell populations, and yield rapidly growing…